Fair value measurements and investments (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Measurements And Investment Disclosure [Abstract]

Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

	March 31, 2020											December 31, 2019
(U.S. Dollars, in thousands)	Level 1		Level 2			Level 3			Total			Total
Assets
Bone Biologics equity securities	$	—	$	—		$	—		$	—		$	219
Total	$	—	$	—		$	—		$	—		$	219
Liabilities
Contingent consideration	$	—	$	—		$	(33,700	)	$	(33,700	)	$	(42,700	)
Deferred compensation plan		—		(1,235	)		—			(1,235	)		(1,255	)
Total	$	—	$	(1,235	)	$	(33,700	)	$	(34,935	)	$	(43,955	)

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

(U.S. Dollars, in thousands)	2020			2019
Contingent consideration at January 1	$	42,700		$	28,560
Increase (decrease) in fair value recognized in acquisition-related amortization and remeasurement		(9,000	)		5,400
Payment made		—			(15,000	)
Contingent consideration at March 31	$	33,700		$	18,960

Schedule of Valuation Methodology and Unobservable Inputs for Level 3 Assets and Liabilities Measured at Fair Value

The following table provides a range of key assumptions used within the valuation as of March 31, 2020.

(U.S. Dollars, in thousands)	Fair Value as of March 31, 2020		Valuation Technique	Unobservable inputs	Range
Contingent consideration	$	33,700	Discounted cash flow	Revenue discount rate	5.0% - 5.3%
				Payment discount rate	6.7% - 7.0%
				Projected year of payment	2021 - 2022

Schedule of Held to Maturity Debt Securities and Warrant Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the eNeura debt security and warrant measured and reflected in the condensed consolidated balance sheets at fair value using significant unobservable inputs (Level 3) prior to the settlement discussed above:

(U.S. Dollars, in thousands)	2020		2019
eNeura debt security and Warrant at January 1	$	—	$	17,820
Gains or losses recorded for the period
Recognized in other comprehensive income (loss)		—		(2,593	)
Change in classification of debt security to held to maturity		—		(15,227	)
Issuance of Warrant as consideration for extension		—		491
eNeura debt security and Warrant at March 31	$	—	$	491